Treatment agent for polyester short fiber spunlace, dilution of treatment agent for polyester short fiber spunlace, first component for polyester short fiber spunlace treatment, second component for polyester short fiber spunlace treatment, and polyester short fiber

Abstract

The objective of this invention is to improve the antistatic properties and carding web uniformity imparted to polyester staple fibers by a polyester staple fiber water injection treatment agent. The polyester staple fiber water injection treatment agent contains a first fatty acid derivative selected from at least one of linoleic acid and alpha-linolenic acid with an epoxide, a second fatty acid derivative selected from at least one of oleic acid and stearic acid with an epoxide, and an organophosphate salt. The non-volatile components of the polyester staple fiber water injection treatment agent contain a total of 10% to 90% by mass of the first and second fatty acid derivatives, and 5% to 80% by mass of the organophosphate salt.

Description

[Technical Field]

[0001] This invention relates to a treatment agent for polyester short fiber water injection, a diluent for the treatment agent for polyester short fiber water injection, a first treatment agent for polyester short fiber water injection, a second treatment agent for polyester short fiber water injection, and polyester short fibers. [Previous Technology]

[0002] For example, in the spinning, stretching, and finishing processes of synthetic fibers, a fiber-adhesive treatment agent is sometimes applied to the surface of the fibers. In addition, a synthetic fiber carding web is generally first produced by a carding process using a carding machine, and then a water needle process is performed to interweave the fibers constituting the carding web to produce nonwoven fabric.

[0003] For example, Patent Document 1 discloses a treatment agent for manufacturing nonwoven fabrics for water injection, which includes fatty acids with 4 to 11 carbon atoms, organophosphates, nonionic surfactants, etc. Patent Document 1 also discloses that by using the above-mentioned treatment agent for nonwoven fabric manufacturing, excellent complexing properties and scum suppression can be obtained, and foaming can be reduced in the water injection process.

[0004] Patent Document 2 discloses a fiber treatment agent for manufacturing water-jet nonwoven fabrics, which contains an ester compound formed from a diacid and a diol, and an alkyl phosphate ester. Patent Document 2 also discloses that by using the above-mentioned fiber treatment agent for manufacturing water-jet nonwoven fabrics, fibers can be endowed with excellent smoothness and softness, and foaming is suppressed during the water-jet process.

[0005] Prior Art Documents Patent Document 1: Japanese Patent No. 6605833 Patent Document 2: Japanese Patent No. 4139130 [Summary of the Invention]

[0006] Problems to be solved by the invention However, it is currently desirable to improve the antistatic properties imparted to polyester staple fibers by fiber treatment agents and the uniformity of the carding web obtained in the carding process.

[0007] Means for solving the problem The inventors conducted research in order to solve the above-mentioned problem and found that polyester short fiber treatment agents containing specific fatty acid derivatives and organophosphate salts are particularly effective.

[0008] The various forms used to solve the above-mentioned problems are recorded.

[0009] Form 1 is a polyester staple fiber water injection treatment agent, characterized in that it contains: a fatty acid derivative (A), a fatty acid derivative (B), and an organophosphate salt (C); the fatty acid derivative (A) is an adduct formed by at least one of linoleic acid and linolenic acid with an epoxide; the fatty acid derivative (B) is an adduct formed by at least one of oleic acid and stearic acid with an epoxide; the non-volatile components of the above polyester staple fiber water injection treatment agent contain a total of 10% to 90% by mass of the above fatty acid derivative (A) and the above fatty acid derivative (B), and 5% to 80% by mass of the above organophosphate salt.

[0010] Form 2 is a polyester staple fiber water injection treatment agent as described in Form 1, wherein the mass proportion of oxyalkylene groups in the molecular structure of the fatty acid derivative (A) and the fatty acid derivative (B) is 50% by mass or less.

[0011] Form 3 is a polyester staple fiber water injection treatment agent as described in Form 1 or 2, wherein when the mass of the fatty acid derivative (A) in the polyester staple fiber water injection treatment agent is set as Am and the mass of the fatty acid derivative (B) is set as Bm, the mass ratio Am / Bm is 0.01 or more and 0.4 or less.

[0012] Form 4 is a polyester staple fiber water injection treatment agent as described in any of Forms 1 to 3, wherein the above-mentioned organophosphate salt (C) is a salt of a phosphate ester having an alkyl group having 11 to 13 carbon atoms.

[0013] Form 5 is a polyester staple fiber water injection treatment agent as described in any of Forms 1 to 4, wherein the non-volatile components of the above-mentioned polyester staple fiber water injection treatment agent contain a total of 30% to 70% by mass of the above-mentioned fatty acid derivative (A) and the above-mentioned fatty acid derivative (B), and 10% to 60% by mass of the above-mentioned organophosphate salt (C).

[0014] Form 6 is a polyester staple fiber water injection treatment agent as described in any of Forms 1 to 5, wherein it further contains a diester (D) formed of polyethylene glycol with a molecular weight of 200 to 800 and a monovalent fatty acid with 12 to 20 carbon atoms.

[0015] Form 7 is a polyester staple fiber water injection treatment agent as described in Form 6, wherein the non-volatile components of the above-mentioned polyester staple fiber water injection treatment agent contain a total of 30% to 70% by mass of the above-mentioned fatty acid derivative (A) and the above-mentioned fatty acid derivative (B), 10% to 60% by mass of the above-mentioned organophosphate salt (C), and 2% to 10% by mass of the above-mentioned diester (D).

[0016] Form 8 is a diluted solution of a polyester staple fiber water injection treatment agent, the key feature of which is that it contains the polyester staple fiber water injection treatment agent described in any one of Forms 1 to 7 and water.

[0017] Form 9 is a first treatment agent for polyester staple fiber water injection, which is used in conjunction with a second treatment agent for polyester staple fiber water injection, wherein: the first treatment agent for polyester staple fiber water injection contains fatty acid derivative (A) and fatty acid derivative (B), and selectively contains a diester formed by polyethylene glycol with a molecular weight of 200 to 800 and a monovalent fatty acid with 12 to 20 carbon atoms; the fatty acid derivative (A) is an adduct formed by at least one of linoleic acid and linolenic acid with an epoxide; the fatty acid derivative (B) is an adduct formed by at least one of oleic acid and stearic acid with an epoxide; and the second treatment agent for polyester staple fiber water injection contains an organophosphate salt (C). The above-mentioned first treatment agent for polyester staple fiber water injection and the above-mentioned second treatment agent for polyester staple fiber water injection are used together such that the non-volatile components of the polyester staple fiber water injection treatment agent obtained by mixing the above-mentioned first treatment agent for polyester staple fiber water injection and the above-mentioned second treatment agent for polyester staple fiber water injection contain a total of more than 10% by mass and less than 90% by mass of the above-mentioned fatty acid derivative (A) and the above-mentioned fatty acid derivative (B), and more than 5% by mass and less than 80% by mass of the above-mentioned organophosphate salt (C).

[0018] Form 10 is a second treatment agent for polyester staple fiber water injection, used in conjunction with a first treatment agent for polyester staple fiber water injection, wherein: the first treatment agent for polyester staple fiber water injection contains fatty acid derivative (A) and fatty acid derivative (B), and selectively contains a diester formed by polyethylene glycol with a molecular weight of 200 to 800 and a monovalent fatty acid with 12 to 20 carbon atoms; the fatty acid derivative (A) is an adduct formed by at least one of linoleic acid and linolenic acid with an epoxide; the fatty acid derivative (B) is an adduct formed by at least one of oleic acid and stearic acid with an epoxide; the second treatment agent for polyester staple fiber water injection contains an organophosphate salt (C). The above-mentioned second treatment agent for polyester staple fiber water injection is used in combination with the above-mentioned first treatment agent for polyester staple fiber water injection, such that the non-volatile components of the polyester staple fiber water injection treatment agent obtained by mixing the above-mentioned second treatment agent for polyester staple fiber water injection and the above-mentioned first treatment agent for polyester staple fiber water injection contain a total of more than 10% by mass and less than 90% by mass of the above-mentioned fatty acid derivative (A) and the above-mentioned fatty acid derivative (B), and more than 5% by mass and less than 80% by mass of the above-mentioned organophosphate salt (C).

[0019] Form 11 is a polyester staple fiber, the key feature of which is that it is coated with a polyester staple fiber water injection treatment agent described in any of Forms 1 to 7.

[0020] Effects of the invention: The present invention can improve the antistatic properties and carding web uniformity of polyester staple fibers by the water injection treatment agent.

Implementation Method

[0021] <First Embodiment> The first embodiment of the present invention will now be described, namely, a treatment agent for polyester staple fiber water injection (hereinafter referred to as the treatment agent). The treatment agent of this embodiment contains the following fatty acid derivative (A), the following fatty acid derivative (B), and an organophosphate salt (C).

[0022] (Fatty acid derivative (A)) Fatty acid derivative (A) is an adduct formed by at least one of linoleic acid and alpha-linolenic acid with an epoxide.

[0023] Epoxides are preferably those with 2 to 4 carbon atoms, and more preferably those with 2 or 3 carbon atoms. Specific examples of epoxides with 2 to 4 carbon atoms include ethylene oxide (hereinafter referred to as EO), propylene oxide (hereinafter referred to as PO), and butylene oxide.

[0024] There is no particular limitation on the number of mol added to the epoxide, but it is preferably 0.1 mol to 20 mol, more preferably 0.5 mol to 18 mol, and most preferably 0.5 mol to 15 mol.

[0025] The addition mole number of the epoxide can also be any combination of the above-mentioned upper and lower limits. The addition mole number of the epoxide represents the number of epoxide moles relative to 1 mole of the target compound in the feedstock. One type of epoxide can be used alone, or two or more types of epoxides can be used in appropriate combinations. When two or more types of epoxides are used, the addition form can be any of block addition, random addition, or a combination of block addition and random addition, without particular limitation.

[0026] The fatty acid derivative (A) may be a dicarboxylic acid with linoleic acid or alpha-linolenic acid bonded to both ends of the epoxide, or a monocarboxylic acid with linoleic acid or alpha-linolenic acid bonded to one end of the epoxide. The fatty acid derivative (A) is preferably a monocarboxylic acid.

[0027] The mass percentage of the oxyalkylene group in the molecular structure of the fatty acid derivative (A) is preferably 50% by mass or less. When the mass percentage of the oxyalkylene group in the molecular structure of the fatty acid derivative (A) is 50% by mass or less, it is easier to suppress foaming caused by the water flow when high-pressure water is jetted during water injection. In other words, foam suppression is improved.

[0028] (Fatty acid derivative (B)) Fatty acid derivative (B) is an adduct formed by at least one of oleic acid and stearic acid with an epoxide.

[0029] The epoxide may be the same as the epoxide in the fatty acid derivative (A) above.

[0030] The fatty acid derivative (B) may be a dicarboxylic acid with oleic acid or stearic acid bonded to both ends of the epoxide, or a monocarboxylic acid with oleic acid or stearic acid bonded to one end of the epoxide. The fatty acid derivative (B) is preferably a monocarboxylic acid. The fatty acid derivative (B) does not contain the diester (D) described later.

[0031] The mass percentage of the oxyalkylene group in the molecular structure of the fatty acid derivative (B) is preferably 50% by mass or less. When the mass percentage of the oxyalkylene group in the molecular structure of the fatty acid derivative (B) is 50% by mass or less, the foam suppression property during high-pressure water jet injection can be improved in the water injection process.

[0032] The mass ratio of oxyalkylene groups in the molecular structure of fatty acid derivative (A) and fatty acid derivative (B) is preferably 50% by mass or less for each. When the mass ratio of oxyalkylene groups in the molecular structure of fatty acid derivative (A) and fatty acid derivative (B) is 50% by mass or less for each, the antifoaming property can be further improved.

[0033] It may also be that the mass percentage of the oxyalkyl group in the molecular structure of either fatty acid derivative (A) or fatty acid derivative (B) is less than 50% by mass.

[0034] (Organophosphate salts (C)) Examples of organophosphate salts (C) include salts of alkyl phosphates, alkenyl phosphates, etc. There are no particular limitations on the alkyl or alkenyl groups constituting the alkyl phosphate; for example, they can be linear or branched.

[0035] Among the alcohols used as raw materials for organophosphate salts (C) are monovalent aliphatic alcohols. Specific examples of monovalent aliphatic alcohols include (1) straight-chain alkanols such as methanol, ethanol, propanol, butanol, pentanol, hexanol, octanol, nonanol, decanol, undecanol, dodecanol, tridecanol, tetradecanol, pentadecanol, hexadecanol, heptadecanol, octadecanol, nonadecanol, eicosane, dodecanol, dodecanol, tridecanol, tetradecanol, pentadecanol, hexadecanol, octadecanol, nonadecanol, triadecanol, etc.; (2) isopropanol, isobutanol, isohexanol, 2-ethylhexanol, isononol, isodecanol, isodecanol, isodecanol, and isodexadecanol. Branched alkanols such as isotetradecaneol, isopentadecanol, isohexadecanol, isohexadecanol, isohexadecanol, isohexadecanol, isohexadecanol, isohexadecanol, isohexadecanol, 2-decyltetradecaneol, isohexadecanol, isohexadecanol, isohexadecanol, isohexadecanol, isohexadecanol, isohexadecanol, isohexadecanol, isohexadecanol, isohexadecanol, etc.; (3) Straight-chain enols such as tetradecenol, hexadecenol, heptadecenol, octadecenol, oleyl alcohol, and nonadecanol; (4) Branched enols such as isohexadecanol and isohexadecanol; (5) Cyclic alkanols such as cyclopentanol and cyclohexanol.

[0036] There are no particular restrictions on the phosphoric acid that constitutes the organic phosphate salt (C). It can be orthophosphoric acid or polyphosphoric acid such as diphosphate.

[0037] Salts of organophosphate salts (C) can be listed as phosphate amine salts, phosphate metal salts, etc.

[0038] The amine constituting the amine salt can be any of the primary amine, secondary amine, and tertiary amine. Specific examples of amines that constitute amine salts include (1) aliphatic amines such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, N-N-diisopropylethylamine, butylamine, dibutylamine, 2-methylbutylamine, tributylamine, octylamine, and dimethyllauramine; (2) aromatic amines or heterocyclic amines such as aniline, N-methylbenzylamine, pyridine, morpholine, piperazine, and their derivatives; (3) alkanolamines such as monoethanolamine, N-methylethanolamine, diethanolamine, triethanolamine, isopropanolamine, diisopropanolamine, triisopropanolamine, dibutylethanolamine, butyl diethanolamine, octyl diethanolamine, and lauryl diethanolamine; (4) arylamines such as N-methylbenzylamine; (5) polyoxyethylene laurylamine ethers such as polyoxyethylene stearylamine ether; and (6) ammonia.

[0039] Examples of metal salts include alkali metal salts and alkaline earth metal salts. Specific examples of alkali metals constituting alkali metal salts include sodium, potassium, and lithium. Alkaline earth metals constituting alkaline earth metal salts include metals of Group 2 elements, such as calcium, magnesium, beryllium, strontium, and barium.

[0040] Specific examples of organophosphate salts (C) include, for example, potassium undecyl phosphate, potassium dodecyl phosphate, potassium tridecyl phosphate, sodium dodecyl phosphate, potassium octadecyl phosphate, potassium octyl phosphate, etc.

[0041] The organophosphate salt (C) is preferably a salt of a phosphate ester of an aliphatic alcohol having 11 to 13 carbon atoms. In other words, the organophosphate salt (C) is preferably a salt of a phosphate ester having 11 to 13 carbon atoms. By using an organophosphate salt (C) of a phosphate ester having 11 to 13 carbon atoms, the antistatic properties of polyester staple fibers can be improved.

[0042] The organophosphate salts (C) may be used alone or in combination with two or more organophosphate salts (C).

[0043] The acid value of the organophosphate salt (C) can be set appropriately, preferably 5-100 KOH-mg / g, more preferably 10-80 KOH-mg / g.

[0044] The acid value of the organic phosphate salt (C) is calculated by dissolving the organic phosphate salt (C) in a mixed solvent of ethanol / xylene = 1 / 2 (volume ratio), setting it on a potentiometric titration device, titrating it with a 0.1 mol / L potassium hydroxide methanol standard solution, and then calculating the value from the following mathematical formula.

[0045] Acid value (KOH - mg / g) = (R × f × 56.11 × 0.1) / S

[0046] In the mathematical formula, f represents the factor of 0.1 mol / L potassium hydroxide methanol standard solution; S represents the amount of sample taken (g, converted from solid content); and R represents the amount of 0.1 mol / L potassium hydroxide methanol standard solution used up to the inversion point (mL).

[0047] (Content) When the mass of fatty acid derivative (A) in the treatment agent is set as Am and the mass of fatty acid derivative (B) is set as Bm, it is preferable that the mass ratio of Am / Bm is 0.01 or more and 0.4 or less.

[0048] When the mass ratio Am / Bm is within the above-mentioned range, the uniformity of the carding web of polyester staple fibers (hereinafter referred to as carding web uniformity) can be further improved.

[0049] The so-called carding web uniformity refers to the property of obtaining a carding web with a smooth texture and good appearance when using polyester short fibers treated with a treatment agent to make a carding web through a carding process.

[0050] The total content of fatty acid derivatives (A) and fatty acid derivatives (B) in the non-volatile components of the treatment agent is 10% by mass or more and 90% by mass or less, preferably 30% by mass or more and 70% by mass or less, and the content of organophosphate salt (C) is 5% by mass or more and 80% by mass or less, preferably 10% by mass or more and 60% by mass or less.

[0051] In one embodiment of this invention, the total content of fatty acid derivative (A) and fatty acid derivative (B) in the non-volatile components of the treatment agent is, for example, 14.6% by mass or more, 18.6% by mass or more, 25% by mass or more, 30% by mass or more, 31% by mass or more, 35% by mass or more, 40% by mass or more, 44% by mass or more, 46% by mass or more, 48% by mass or more, 58% by mass or more, 62% by mass or more, 69.9% by mass or more, 70% by mass or more, 72% by mass or more, or 90% by mass or more. Similarly, the total percentage of fatty acid derivatives (A) and fatty acid derivatives (B) in the non-volatile components of the treatment agent is, for example, 90% by mass or less, 72% by mass or less, 70% by mass or less, 69.9% by mass or less, 62% by mass or less, 58% by mass or less, 48% by mass or less, 46% by mass or less, 44% by mass or less, 40% by mass or less, 35% by mass or less, 31% by mass or less, 30% by mass or less, 25% by mass or less, 18.6% by mass or less, or 14.6% by mass or less.

[0052] In one embodiment of this invention, the total content of organophosphate salt (C) in the non-volatile components of the treatment agent is, for example, 5% by mass or more, 10% by mass or more, 13% by mass or more, 15% by mass or more, 20% by mass or more, 24.1% by mass or more, 32% by mass or more, 40% by mass or more, 47% by mass or more, 50% by mass or more, 55% by mass or more, 60% by mass or more, 60.1% by mass or more, 65% by mass or more, 70% by mass or more, or 78% by mass or more. Similarly, the total percentage of organophosphate salts (C) in the non-volatile components of the treatment agent is, for example, less than 78% by mass, less than 70% by mass, less than 65% by mass, less than 60.1% by mass, less than 60% by mass, less than 55% by mass, less than 50% by mass, less than 47% by mass, less than 40% by mass, less than 32% by mass, less than 24.1% by mass, less than 20% by mass, less than 15% by mass, less than 13% by mass, less than 10% by mass, or less than 5% by mass.

[0053] When the contents of fatty acid derivative (A), fatty acid derivative (B), and organic phosphate salt (C) are within the above-mentioned value range, antistatic properties, antifoaming properties, and hydrophilicity can be improved simultaneously.

[0054] The total amount of fatty acid derivatives (A), fatty acid derivatives (B), and organophosphate salts (C) in the non-volatile components of the treatment agent may not be 100% by mass. As described below, for example, diesters (D) or other components (E) may also be included.

[0055] The non-volatile components of the treatment agent mentioned in this specification refer to the residue after the treatment agent has been heated at 105°C for 2 hours.

[0056] The treatment agent may further contain the following diester (D).

[0057] (Dearylester (D)) Diester (D) is a diester formed by polyethylene glycol with a molecular weight of 200 to 800 and a monovalent fatty acid with 12 to 20 carbon atoms.

[0058] By using a treatment agent containing the above-mentioned diester (D), the hydrophilicity and carding web uniformity of polyester staple fibers can be improved.

[0059] The molecular weight mentioned above refers to the mass average molecular weight.

[0060] Examples of monovalent fatty acids with 12 to 20 carbon atoms include dodecanoic acid (lauric acid), tridecanoic acid, tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitic acid), heptadecanoic acid, octadecanoic acid (stearic acid), nonadecanoic acid, eicosanoic acid, etc.

[0061] Specific examples of diester (D) include, for example, a diester formed by polyethylene glycol with a mass average molecular weight of 200 and oleic acid (hereinafter referred to as polyoxyethylene (mass average molecular weight 200) dioleate), a diester formed by polyethylene glycol with a mass average molecular weight of 800 and oleic acid (hereinafter referred to as polyoxyethylene (mass average molecular weight 800) dioleate), a diester formed by polyethylene glycol with a mass average molecular weight of 400 and lauric acid (hereinafter referred to as polyoxyethylene (mass average molecular weight 400) dilaurate), and a diester formed by polyethylene glycol with a mass average molecular weight of 600 and lauric acid (hereinafter referred to as polyoxyethylene (mass average molecular weight 600) dilaurate), etc.

[0062] The diesters (D) can be used alone or in combination with two or more types of diesters (D).

[0063] There are no restrictions on the method for determining the mass average molecular weight of diester (D), and known methods can be used. For example, it can be determined by gel permeation chromatography.

[0064] (Content) The non-volatile components of the treatment agent preferably contain a total of 30% to 70% by mass of fatty acid derivatives (A) and fatty acid derivatives (B), 10% to 60% by mass of organic phosphate salt (C), and 2% to 10% by mass of diester (D).

[0065] In one embodiment of this invention, the content of diester (D) in the non-volatile components of the treatment agent is, for example, 1% or more by mass, 1.9% or more by mass, 2.4% or more by mass, 4% or more by mass, 5% or more by mass, 10% or more by mass, or 17% or more by mass. Similarly, the content of diester (D) in the non-volatile components of the treatment agent is, for example, 17% or less by mass, 10% or less by mass, 5% or less by mass, 4% or less by mass, 2.4% or less by mass, 1.9% or less by mass, or 1% or less by mass.

[0066] The total amount of fatty acid derivatives (A), fatty acid derivatives (B), organophosphate salts (C), and diesters (D) in the non-volatile components of the treatment agent may not be 100% by mass. As described below, other components (E) may also be included, for example.

[0067] When the contents of fatty acid derivative (A), fatty acid derivative (B), organic phosphate salt (C), and diester (D) are within the above-mentioned value range, the uniformity of the carding web of polyester staple fiber or the emulsion stability of the treatment agent can be improved.

[0068] (Other Components (E)) The treatment agent of this embodiment may also contain other components (E). Examples of other components (E) include stabilizers, antistatic agents, adhesives, antioxidants, ultraviolet absorbers, surfactants, pH adjusters, higher alcohols, and other components commonly used in treatment agents. Examples of surfactants include nonionic surfactants. Higher alcohols refer to monohydric alcohols with 6 or more carbon atoms.

[0069] Specific examples of other components (E) include, for instance, compounds formed by the random addition of 1 mol of castor oil to 9 mol of EO and 9 mol of PO; compounds formed by the random addition of 1 mol of castor oil to 7 mol of EO and 3 mol of PO; compounds formed by the random addition of 1 mol of hardened castor oil to 5 mol of EO and 5 mol of PO; and compounds formed by the random addition of 1 mol of hardened castor oil to 9 mol of EO and 3 mol of PO. Compounds formed from 9 moles; sodium salts of secondary alkyl sulfonates with 11 to 14 carbon atoms; lauryl alcohol; oleic acid; potassium octanoate; ester compounds obtained by dehydration condensation of 1 mole of sebacic acid with 0.1 mole of polyoxyethylene polyoxypropylene glycol (random polymer: mass average molecular weight 13000, EO content ratio 75% by mass), 0.5 mole of polyethylene glycol (mass average molecular weight 600), and 0.4 mole of polyethylene glycol (mass average molecular weight 400); propylene glycol; potassium salt of ethylene glycol monobutyl ether phosphate; polyoxyethylene monolaurate (mass average molecular weight 400), etc.

[0070] The other ingredients (E) may be used alone or in combination with two or more other ingredients (E). In other words, the other ingredients (E) may contain only at least one of the above.

[0071] There are no particular restrictions on the content of other components (E), and other components (E) may be included without impairing the effect of the present invention.

[0072] The content of other components (E) in the non-volatile components of the treatment agent can be set, for example, to be 60% or less by mass, 50% or less by mass, 40% or less by mass, 30% or less by mass, 20% or less by mass, 10% or less by mass, or 0% by mass. Alternatively, it can be set to 5% or more by mass or 10% or more by mass. The content of other components (E) can also be any combination of the above upper and lower limits.

[0073] (Preservation form) The treatment agent may be configured as a dosage form 1 containing the above-mentioned fatty acid derivative (A), fatty acid derivative (B) and organophosphate salt (C), and from the viewpoint of improving the stability of the formulation or preservation stability, it may also be configured as a dosage form 2 treatment agent as shown below.

[0074] The 2-formulation treatment agent comprises, in groups: a first treatment agent for polyester staple fiber water injection containing fatty acid derivatives (A), fatty acid derivatives (B), and optionally a diester (D) (hereinafter referred to as the first treatment agent), and a second treatment agent for polyester staple fiber water injection containing an organophosphate salt (C) (hereinafter referred to as the second treatment agent). Either or both of the first treatment agent and the second treatment agent contain other components (E).

[0075] The second dosage form treatment agent is prepared by combining the first treatment agent and the second treatment agent in different ways before use, such as during storage or distribution. When using the second dosage form treatment agent, the first treatment agent and the second treatment agent are mixed to prepare a mixture.

[0076] (Solvent) The treatment agent of the first embodiment may also be mixed with a solvent as appropriate to prepare a composition containing a polyester short fiber water injection treatment agent or a polyester short fiber water injection treatment agent dilution, and stored or distributed in such form.

[0077] The solvent is, for example, a solvent with a boiling point of 105°C or less at one atmosphere. Examples of solvents include water and organic solvents. Specific examples of water include ion-exchanged water, distilled water, hard water, soft water, etc. Specific examples of organic solvents include lower alcohols such as ethanol and propanol, and low-polarity solvents such as hexane. One type of solvent may be used alone, or two or more types of solvents may be used in appropriate combinations. Among these, from the viewpoint of excellent dispersibility or solubility of each component, polar solvents such as water and lower alcohols are preferred, and from the viewpoint of excellent operability, water is more preferred.

[0078] <Effects and Effects of the First Embodiment> (1-1) The treatment agent of the first embodiment described above contains the above-mentioned fatty acid derivative (A), fatty acid derivative (B), and organophosphate salt (C). Therefore, the antistatic properties and carding web uniformity imparted by the treatment agent to polyester staple fibers can be improved.

[0079] (1-2) Furthermore, by containing the above-mentioned diester (D), the hydrophilicity and carding web uniformity imparted by the treatment agent to the polyester staple fiber can be further improved.

[0080] <Second Embodiment> Next, a second embodiment of the present invention will be described, namely, a diluent for a polyester staple fiber water injection treatment agent (hereinafter referred to as diluent). The description will focus on the differences from the first embodiment.

[0081] The diluent of this embodiment contains the above-mentioned treatment agent and water. By mixing the treatment agent with water, the diluent is used as an emulsion. Specific examples of water include ion-exchanged water, distilled water, hard water, and soft water. Among these, ion-exchanged water and distilled water are preferred.

[0082] There are no particular limitations on the method of preparing the diluent. For example, a method of adding a predetermined amount of treatment agent to pre-measured water can be used. Furthermore, it can be prepared by using known mechanical emulsification methods such as homogenizers or homogenizers.

[0083] The diluent may also contain known solvents other than water. Examples of solvents other than water include the organic solvents mentioned above.

[0084] There are no particular limitations on the concentration of the treatment agent in the diluent. The concentration of the treatment agent can be set to, for example, 30% by mass or more, 40% by mass or more, 50% by mass or more, or 60% by mass or more. In addition, it can be set to 95% by mass or less, 90% by mass or less, 80% by mass or less, or 70% by mass or less. The concentration of the treatment agent can also be any combination of the above upper and lower limits.

[0085] <Function and Effect of the Second Embodiment> In addition to the function and effect of the first embodiment, the second embodiment also has the following function and effect.

[0086] (2-1) The diluent of the second embodiment described above contains the above-mentioned treatment agent and water. Therefore, the treatment agent can be applied to the polyester staple fiber in the form of an emulsion. In addition, the presence of water in the solvent helps to maintain good operability of the diluent.

[0087] <Third Embodiment> Next, a third embodiment of the present invention will be described, namely, a first treatment agent (first treatment agent) for polyester staple fiber water injection. The description will focus on the differences from the first embodiment. The first treatment agent contains fatty acid derivative (A) and fatty acid derivative (B), and optionally contains diester (D).

[0088] The first treatment agent is used in conjunction with a second treatment agent for polyester staple fiber water injection containing an organophosphate salt (C) (hereinafter referred to as the second treatment agent). In detail, the treatment agent is prepared as a mixture of the first treatment agent and the second treatment agent only when it is used.

[0089] The fatty acid derivative (A), fatty acid derivative (B), organophosphate salt (C), and diester (D) are the same as those described in the first embodiment. The first treatment agent may also contain the other components (E) mentioned above.

[0090] (Solvent) The first treatment agent of the third embodiment can be mixed with a solvent as needed to prepare a first treatment agent dilution for polyester staple fiber water injection (hereinafter referred to as the first treatment agent dilution). The first treatment agent can also be stored or distributed in the form of the first treatment agent dilution. According to this configuration, dilution with a solvent or mixing with a second treatment agent is only required during use, which can improve the miscibility and the stability of the composition. The solvent can be one exemplified in the first embodiment.

[0091] <Function and Effect of the Third Embodiment> In addition to the functions and effects of the first and second embodiments, the third embodiment also has the following functions and effects.

[0092] (3-1) The first treatment agent of the third embodiment contains fatty acid derivative (A), fatty acid derivative (B), and optionally contains diester (D), and is used in conjunction with the second treatment agent containing organophosphate salt (C). Therefore, the formulation stability or storage stability of the first treatment agent during storage or distribution can be improved. Furthermore, the composition of the obtained treatment agent can be adjusted by adjusting the mixing ratio with the second treatment agent. In addition, the first treatment agent and the second treatment agent can be distributed separately.

[0093] <Fourth Embodiment> Next, a fourth embodiment of the present invention, namely a second treatment agent (second treatment agent) for polyester staple fiber water injection, will be described. The description will focus on the differences from the first to third embodiments. The second treatment agent contains an organophosphate salt (C). The second treatment agent is used in conjunction with a first treatment agent containing fatty acid derivatives (A), fatty acid derivatives (B), and optionally a diester (D). In detail, the treatment agent is prepared as a mixture of the first treatment agent and the second treatment agent only when used.

[0094] The fatty acid derivative (A), fatty acid derivative (B), organophosphate salt (C), and diester (D) are the same as those described in the first embodiment. The second treatment agent may also contain the other components (E) mentioned above.

[0095] (Solvent) The second treatment agent of the fourth embodiment can be mixed with a solvent as needed to prepare a second treatment agent dilution for polyester staple fiber water injection (hereinafter referred to as the second treatment agent dilution). The second treatment agent can also be stored or distributed in the form of the second treatment agent dilution. According to this configuration, dilution with a solvent or mixing with the first treatment agent is only required during use, which improves the miscibility and stability of the composition. The solvent can be one exemplified in the first embodiment.

[0096] <Function and Effect of the Fourth Embodiment> In addition to the functions and effects of the above-described embodiments, the fourth embodiment also has the following functions and effects.

[0097] (4-1) The second treatment agent of the fourth embodiment contains an organophosphate salt (C) and is used in combination with the first treatment agent containing fatty acid derivatives (A), fatty acid derivatives (B), and optionally a diester (D). Therefore, the formulation stability or storage stability of the second treatment agent during storage or distribution can be improved. Furthermore, the composition of the obtained treatment agent can be adjusted by adjusting the mixing ratio with the first treatment agent. In addition, the second treatment agent and the first treatment agent can be distributed separately.

[0098] <Fifth Embodiment> Next, the fifth embodiment of the present invention, namely polyester staple fiber, will be described.

[0099] The polyester staple fiber of this embodiment is a treated polyester staple fiber with the treatment agent of the first embodiment attached to its surface. Modified polyester staple fiber can be obtained by attaching the treatment agent to the surface of the polyester staple fiber.

[0100] (Length of polyester staple fiber) Polyester staple fiber usually refers to fibers called "staple" or "shortcut," excluding long fibers called "filament." "Staple" refers to short fibers with a length of approximately 3cm to 7cm. "Shortcut" refers to short fibers with a length of less than 1cm. In other words, polyester staple fiber refers to short fibers with a length of approximately 7cm or less.

[0101] As described below, when using polyester staple fibers to produce water-jet nonwoven fabric, the fibers constituting the nonwoven fabric may also include the aforementioned long fibers. More specifically, the treatment agent of the present invention is not only applicable to polyester staple fibers, but also to long fibers other than polyester staple fibers mixed in the nonwoven fabric.

[0102] (Types of polyester staple fibers) Specific examples of polyester staple fibers include polyethylene terephthalate, polybutylene terephthalate, polyethylene terephthalate-isophthalate, polyether polyester, etc.

[0103] (Adhesion treatment of the treatment agent) The treatment agent of the first embodiment does not have any particular limitation on the amount of polyester staple fiber to which it is adhered. Preferably, the amount of solvent-free treatment agent adhering to the polyester staple fiber is 0.1% to 2% by mass, and more preferably, the amount of solvent-free treatment agent adhering to the polyester staple fiber is 0.3% to 1.2% by mass.

[0104] A method for attaching the treatment agent to the polyester staple fiber may be, for example, by using the diluent of the second embodiment, and by a known method, such as impregnation, spraying, rolling, or guided oiling using a metering pump.

[0105] (Method for Manufacturing Nonwoven Fabric) The polyester staple fibers of this embodiment can also be used to manufacture nonwoven fabric by the following method. Specifically, nonwoven fabric can be obtained by the following steps: Step 1: Applying the treatment agent of the first embodiment to the polyester staple fibers. Step 2: Passing the polyester staple fibers with the treatment agent applied in Step 1 through a carding machine to obtain a carded web. Step 2 is called the carding process. Step 3: Spraying high-pressure water jets onto the carded web obtained in Step 2 using a water jetting method to interweave the fibers and obtain nonwoven fabric. Step 3 is called the water jetting process.

[0106] Nonwoven fabric can be manufactured through the above steps. Since nonwoven fabric is made by interlacing fibers together using a water-jet nonwoven process, it can also be called water-jet nonwoven fabric.

[0107] In step 1, when using a two-component treatment agent, a diluted solution of the treatment agent containing a solvent such as water, the first treatment agent of the third embodiment, and the second treatment agent of the fourth embodiment is first prepared, and then applied to the polyester staple fiber. A method for preparing the diluted solution, for example, is to add the first treatment agent and the second treatment agent to water.

[0108] In the form of using the first treatment agent and the second treatment agent together, the mixing ratio of each agent can be arbitrarily changed. Therefore, even under conditions where manufacturing equipment is different or manufacturing conditions vary such as different climates such as temperature and humidity, the treatment agent or diluent with the best properties for imparting fiber characteristics or fiber manufacturing characteristics can be easily prepared by finely adjusting the mixing ratio.

[0109] There is no particular limitation on the ratio of the first treatment agent to the second treatment agent, but it is preferable that the mass ratio of the non-volatile components is 95 / 5 to 5 / 95 for the first treatment agent and the second treatment agent. By limiting it to this range, operability can be improved.

[0110] In order to emulsify the treatment agent, the treatment agent may also be mixed with the solvent and stirred using a known mixer, such as a homogenizer, a gel mill, a linear mixer, etc.

[0111] For example, the polyester staple fiber may be given the diluent obtained in the above manner in at least one of the spinning step, stretching step and post-processing step of the polyester staple fiber, thereby obtaining polyester staple fiber with the treatment agent attached.

[0112] <Function and Effect of the Fifth Embodiment> In addition to the functions and effects of the above-described embodiments, the fifth embodiment also has the following functions and effects.

[0113] (5-1) The polyester staple fiber is coated with the treatment agent of the first embodiment. Therefore, the antistatic properties and carding web uniformity of the polyester staple fiber can be improved. By improving the antistatic properties of the polyester staple fiber, the process passability of the polyester staple fiber can be maintained well during the carding process. In addition, by improving the carding web uniformity of the polyester staple fiber, the unevenness of thickness or density in the subsequent water needle process can be reduced, thereby obtaining a nonwoven fabric of better quality. Therefore, the nonwoven fabric made using the polyester staple fiber of the present invention is preferably suitable for applications such as wet wipes or masks.

[0114] (5-2)In addition, when it is a multi-dosage form, since the first and second treatment agents are added to the solvent for preparation only when used, the stability or storage stability of the preparation can be maintained well.

[0115] Example

[0116] The following examples are provided to illustrate the structure and effects of the present invention in more detail, but the present invention is not limited to these examples. In the following descriptions of examples and comparative examples, % represents mass %, and parts represent parts by mass.

[0117] Test Category 1 (Preparation of Treatment Agent for Water-Based Injection of Polyester Staple Fibers)

[0118] (Example 1-1) 950g of water was heated to 50°C and the following components were mixed while stirring to obtain a 5% by mass aqueous solution of the polyester short fiber water injection treatment agent of Example 1. Fatty acid derivative (A): Compound (A-1) formed by the addition of 1 mol of linoleic acid to 3 mol of EO 3 mol (A-1) 3.5 g; Fatty acid derivative (B): Compound (B-1) formed by the addition of 1 mol of oleic acid to 3 mol of EO 3 mol (B-1) 16.5 g; Organophosphate salt (C): Potassium undecyl phosphate (C-1) 20 g; Diester (D): Polyoxyethylene (mass average molecular weight 200) dioleate (D-1) 2 g, Polyoxyethylene (mass average molecular weight 800) dioleate (D-2) 0.5 g; Other components (E): Compound (E-1) formed by the random addition of 1 mol of castor oil to 9 mol of EO 9 mol and 9 mol of PO 9 mol (E-1) 1.5 g, Compound (E-2) formed by the random addition of 1 mol of castor oil to 7 mol of EO 7 mol and 3 mol of PO 3 mol (E-2) 5 g, Compound (E-3) formed by the random addition of 1 mol of hardened castor oil to 5 mol of EO 5 mol and 5 mol of PO 5 mol (E-3) 1 g.

[0119] (Examples 1-2 to 1-22, Comparative Examples 1 to 5) Using the same method as in Example 1, each treatment agent of Examples 1-2 to 1-22 and Comparative Examples 1 to 5 was prepared using the components shown in Table 1.

[0120] The types and contents of fatty acid derivatives (A), fatty acid derivatives (B), organophosphate salts (C), diesters (D), other components (E), and the mass ratio of fatty acid derivatives (A) to fatty acid derivatives (B) in the treatment agents of each example are shown in the columns "Fatty Acid Derivatives (A)," "Fatty Acid Derivatives (B)," "Organophosphate Salts (C)," "Diesters (D)," "Other Components (E)," and "Am / Bm" of Table 1, respectively.

[0121] Table 1 category Polyester staple fiber water injection treatment agent Evaluation results Fatty acid derivatives (A) Fatty acid derivatives (B) Organic phosphate salts (C) Diester (D) Other ingredients (E) Am / Bm Antistatic electrical Combing web Uniformity Antifoaming properties hydrophilic lotion stability type % type % type % type % type % Example 1-1 A-1 7 B-1 33 C-1 40 D-1 D-2 4 1 E-1 E-2 E-3 3 10 2 0.21 3 4 3 3 3 Examples 1-2 A-1 7 B-1 33 C-2 40 D-3 D-4 4 1 E-2 E-4 E-5 3 10 2 0.21 3 4 3 3 3 Examples 1-3 A-1 8 B-1 40 C-1 47 D-4 5 - - 0.20 3 4 3 3 3 Actual example 1-4 A-1 4 B-1 27 C-2 50 D-3 4 E-4 E-5 E-6 E-7 E-12 10 2 1 1 1 0.15 3 4 3 3 3 Actual example 1-5 A-2 2 B-1 60 C-3 13 D-1 10 E-1 E-5 7 8 0.03 3 4 3 3 3 Actual example 1-6 A-3 4 B-1 36 C-3 50 D-3 10 - - 0.11 3 4 3 3 3 Examples 1-7 A-1 10 B-2 25 C-4 60 D-2 5 - - 0.40 3 4 3 3 3 Examples 1-8 A-1 7 B-1 39 C-3 32 D-3 5 E-4 E-5 E-6 E-7 12 3 1 1 0.18 3 4 3 3 3 Examples 1-9 A-1 2 B-1 70 C-3 15 D-2 10 E-1 3 0.03 2 4 3 3 3 Examples 1-10 A-1 10 B-3 60 C-4 5 D-2 10 E-1 15 0.17 2 4 3 3 2 Examples 1-11 A-1 5 B-1 25 C-2 65 D-3 5 - - 0.20 3 4 3 2 3 Examples 1-12 A-3 4.4 B-1 39.6 C-3 55 D-3 1 - - 0.11 3 3 3 3 3 Examples 1-13 A-1 8 B-1 50 C-2 20 D-3 17 E-2 5 0.16 3 4 3 3 2 Examples 1-14 A-1 9.6 B-1 60.3 C-2 24.1 - - E-2 6 0.16 3 3 3 2 3 Examples 1-15 A-1 5 B-1 20 C-2 60.1 - - E-2 14.9 0.25 3 3 2 2 3 Examples 1-16 A-1 9.6 B-1 60.3 C-5 24.1 - - E-2 6 0.16 2 3 3 2 3 Examples 1-17 A-1 20.8 B-1 49.1 C-5 24.1 - - E-2 6 0.42 2 2 3 2 2 Examples 1-18 A-4 20 B-5 70 C-6 10 - - - - 0.29 2 3 2 2 3 Examples 1-19 A-4 20.8 B-4 49.1 C-5 24.1 - - E-2 6 0.42 2 2 2 2 3 Examples 1-20 A-5 20.8 B-5 49.1 C-5 24.1 - - E-2 6 0.42 2 2 2 2 3 Examples 1-21 A-1 2.6 B-1 12 C-1 78 D-1 D-2 1.5 0.4 E-1 E-2 E-3 1.1 3.7 0.7 0.21 3 4 2 3 3 Examples 1-22 A-1 2.4 B-1 16.2 C-3 70 D-3 D-4 2.2 0.2 E-4 E-5 E-6 E-7 E-12 6 1.2 0.6 0.6 0.6 0.15 3 4 2 3 3 Comparative Example 1 - - B-5 87.5 C-6 12.5 - - - - 0.00 2 1 2 2 2 Comparative Example 2 A-1 39.9 - - C-5 48.1 - - E-2 12 - 3 1 1 2 3 Comparative Example 3 A-1 12.6 B-1 79.5 - - - - E-2 7.9 0.16 1 2 2 3 1 Comparative Example 4 - - - - C-6 12 - - E-9 E-10 E-11 57 14 17 - 3 1 2 2 2 Comparative Example 5 - - - - C-2 10 - - E-8 90 - 3 1 3 1 2

[0122] The details of the fatty acid derivatives (A), fatty acid derivatives (B), organophosphate salts (C), diesters (D), and other components (E) listed in Table 1 are as follows.

[0123] <Fatty Acid Derivatives (A)> Fatty acid derivatives (A) are A-1 to A-5 as shown in Table 2 below.

[0124] The types of fatty acid derivatives (A) and the mass ratio of oxyalkyl groups in their molecular structure are shown in the "Types of Fatty Acid Derivatives (A)" and "Mass Ratio of Oxyalkyl Groups" columns in Table 2, respectively.

[0125] Table 2 Types of fatty acid derivatives (A) Mass percentage of oxyalkylene groups (%) A-1 Compound formed by the addition of 1 mol of linoleic acid to 3 mol of EO 32.00 A-2 The compound formed by the addition of 1 mol of linoleic acid to PO3 mol 37.50 A-3 A compound formed by the random addition of 1 mol of linoleic acid to 1 mol of EO and 3 mol of PO. 43.10 A-4 Compound formed by the addition of 1 mol of linoleic acid to 8 mol of EO 55.65 A-5 A compound formed by the addition of 1 mol of linoleic acid to 8 mol of EO. 55.80

[0126] <Fatty Acid Derivatives (B)> Fatty acid derivatives (B) are B-1 to B-5 as shown in Table 3 below.

[0127] The types of fatty acid derivatives (B) and the mass ratio of oxyalkyl groups in their molecular structure are shown in the "Types of Fatty Acid Derivatives (B)" column and the "Mass Ratio of Oxyalkyl Groups" column in Table 3, respectively.

[0128] Table 3 Types of fatty acid derivatives (B) Mass percentage of oxyalkylene groups (%) B-1 ​​The compound formed by the addition of 1 mol of oleic acid to 3 mol of EO 31.85 B-2 Compound formed by the addition of 1 mol of stearic acid to 5 mol of EO 43.61 B-3 A compound formed by the sequential block addition of 1 mol of oleic acid to 2 mol of EO and 2 mol of PO. 41.40 B-4 Compound formed by the addition of 1 mol of oleic acid to 8 mol of EO 55.48 B-5 Compound formed by the addition of 1 mol of stearic acid to 15 mol of EO. 69.80

[0129] <Organophosphate salts (C)> The organic phosphate salts (C) are C-1 to C-6 as shown in Table 4 below.

[0130] The alkyl straight-chain ratio, alkyl carbon number, acid value, and P-nuclear NMR integral ratio of the organophosphate salt (C) are shown in the "alkyl straight-chain ratio", "alkyl carbon number", "acid value", and "P-nuclear NMR integral ratio" columns of Table 4, respectively. In Table 4, "monomer", "diomer", and "multiomer" refer to "monoester", "diester", and "diphosphoester", respectively. The P-nuclear NMR integral ratio can be determined by known methods.

[0131] Table 4 Types of organophosphate salts (C) alkyl Straight chain percentage (%) Alkyl carbon number Acid value (KOH - mg / g) P-core NMR integral ratio (%) inorganic matter monomer Double body multibody C-1 Potassium undecyl phosphate 100 11 60 25 54 20 1 C-2 ​Potassium dodecyl phosphate 100 12 75 25 52 twenty three 0 C-3 Potassium tridecyl phosphate 62 13 65 18 53 twenty four 5 C-4 Sodium dodecyl phosphate 100 12 75 5 44 38 13 C-5 Potassium octadecyl phosphate 100 18 20 5 40 35 20 C-6 Potassium octyl phosphate 100 8 50 5 40 44 11

[0132] <Dearyl Acetate (D)> D-1: Polyoxyethylene (mass average molecular weight 200) dioleate D-2: Polyoxyethylene (mass average molecular weight 800) dioleate D-3: Polyoxyethylene (mass average molecular weight 400) dilaurate D-4: Polyoxyethylene (mass average molecular weight 600) dilaurate

[0133] <Other Components (E)> E-1: Compound formed by random addition of 1 mol of castor oil to 9 mol of EO and 9 mol of PO; E-2: Compound formed by random addition of 1 mol of castor oil to 7 mol of EO and 3 mol of PO; E-3: Compound formed by random addition of 1 mol of hardened castor oil to 5 mol of EO and 5 mol of PO; E-4: Compound formed by random addition of 1 mol of hardened castor oil to 9 mol of EO and PO. Compound E-5: Sodium salt of secondary alkyl sulfonate with carbon numbers 11-14, formed from 9 moles; E-6: Lauryl alcohol; E-7: Oleic acid; E-8: Potassium octanoate; E-9: Sebacic acid; 1 mole of polyoxyethylene polyoxypropylene glycol (random polymer: mass average molecular weight 13000, EO content ratio 75% by mass), 0.1 mole of polyethylene glycol (mass average molecular weight 600), 0.5 mole of polyethylene glycol (mass average molecular weight 400), and 0.4 mole of polyethylene glycol (mass average molecular weight 400) were dehydrated and condensed to obtain ester compounds E-10: Propylene glycol; E-11: Potassium salt of ethylene glycol monobutyl ether phosphate; E-12: Polyoxyethylene monolaurate (mass average molecular weight 400).

[0134] Test Category 2 (Preparation of polyester staple fiber treated cotton)

[0135] A 5% by mass aqueous solution of the polyester staple fiber water injection treatment agent prepared in Test Category 1 was applied to polyester staple fibers (1.5 dtex fineness, 38 mm fiber length) using a spray oiling method. The amount of non-volatile components of the treatment agent applied was 0.14% by mass. Then, the raw cotton with the treatment agent applied was dried in a hot air dryer at 80°C for 2 hours, and then conditioned overnight at 25°C × 40% RH. The conditioned cotton was designated as polyester staple fiber treated cotton (hereinafter referred to as treated cotton).

[0136] Test Category 3 (Antistatic Properties)

[0137] 5g of the above-treated cotton was conditioned in a constant temperature room at 20°C and 45% RH for 24 hours, and then the resistance (Ω) was measured using a resistance meter (SM-5E type manufactured by Toa Denpa Kogyo Co., Ltd.), and evaluated using the following evaluation criteria. The results are shown in the "Antistatic Properties" column of Table 1.

[0138] ・Evaluation criteria for antistatic properties: 3 (Good): Surface resistivity less than 1.0 × 10⁹ Ω; 2 (Fair): Surface resistivity greater than 1.0 × 10⁹ Ω but less than 1.0 × 10¹⁰ Ω; 1 (Poor): Surface resistivity greater than 1.0 × 10¹⁰ Ω.

[0139] Test Category 4 (Card Web Uniformity)

[0140] 20g of the above-treated cotton was conditioned in a constant temperature chamber at 20°C and 65% RH for 24 hours, and then applied to a known carding machine. The texture of the discharged carded web was evaluated by visual inspection using the following evaluation criteria. The results are shown in the "Carded Web Uniformity" column of Table 1.

[0141] ・Evaluation criteria for carding web uniformity: 4 (Excellent): The texture of the carding web is uniform and the appearance is very good. 3 (Good): The texture of the carding web has a small amount of disorder, but the appearance is good. 2 (Fair): The texture of the carding web is slightly disordered. 1 (Poor): The texture of the carding web is disordered.

[0142] Test Category 5 (Foam Suppression)

[0143] 15g of the above-treated foam was placed in 150g of water, and after 2 hours, the foam was pressed using a known manual juicer. 10g of the pressed liquid was placed in a 25mL graduated cylinder with a stopper, and then vigorously shaken for 30 seconds. After standing for 5 minutes, the height from the water surface to the top surface of the foam was measured, and the results were evaluated using the following evaluation criteria. The results are shown in the "Foam Suppression" column of Table 1.

[0144] ・Evaluation criteria for foam suppression: 3 (Good): Foam less than 3mm; 2 (Fair): Foam more than 3mm but less than 10mm; 1 (Poor): Foam more than 10mm.

[0145] Test Category 6 (Hydrophilicity)

[0146] Place 5g of the above-treated cotton into a 3g metal basket and add 1L of water. Measure the time required for the treated cotton to be completely immersed in water and evaluate it using the following evaluation criteria. The results are shown in the "Hydrophilicity" column of Table 1.

[0147] ・Evaluation criteria for hydrophilicity: 3 (Good): Time required for complete immersion in water is less than 5 seconds; 2 (Fair): Time required for complete immersion in water is more than 5 seconds but less than 10 seconds; 1 (Poor): Time required for complete immersion in water is more than 10 seconds.

[0148] Test Category 7 (Emulsion Stability)

[0149] 20 g of 5% by mass aqueous solution of each treatment agent was placed in a test tube with a diameter of 18 mm, and then placed in a constant temperature room at 20°C. The state of the aqueous solution was visually confirmed after 24 hours, and evaluated using the following evaluation criteria. The results are shown in the "Emulsion Stability" column of Table 1.

[0150] ・Emulsion stability evaluation criteria 3 (Good): No precipitation or separation, exhibiting a homogeneous state 2 (Fair): Although no precipitation is visible, separation occurs 1 (Poor): Precipitation occurs, exhibiting an uneven state

[0151] Test Category 8 (Preparation of the first treatment agent dilution for 2-formulation treatment agents)

[0152] (First treatment agent diluent (I-1) to (I-22)) Weigh each component to achieve the content ratio shown in Table 5, stir and mix them to prepare the first treatment agent diluent (first treatment agent diluent (I-1) to (I-22)) for polyester short fiber water injection.

[0153] The types and contents of fatty acid derivatives (A), fatty acid derivatives (B), diesters (D), other components (E), and water content in the first treatment agent diluent (I-1) to (I-22) are shown in the columns “Fatty acid derivatives (A)”, “Fatty acid derivatives (B)”, “Diesters (D)”, “Other components (E)”, and “Solvent” of Table 5, respectively.

[0154] Table 5 category First treatment agent diluent evaluate First treatment agent solvent preparation stability Fatty acid derivatives (A) Fatty acid derivatives (B) Diester (D) Other ingredients (E) type share type share type share type share type Relative to a total of 100 parts by mass of the first treatment agent I-1 A-1 11.7 B-1 55 D-1 D-2 6.7 1.7 E-1 E-2 E-3 5 16.6 3.3 Water 8 2 I-2 A-1 11.7 B-1 55 D-3 D-4 6.7 1.7 E-2 E-4 E-5 5 16.6 3.3 Water 8 2 I-3 A-1 15.1 B-1 75.5 D-4 9.4 - - Water 8 2 I-4 A-1 8 B-1 54 D-3 8 E-4 E-5 E-6 E-7 E-12 20 4 2 2 2 Water 8 2 I-5 A-2 2.3 B-1 69 D-1 11.5 E-1 E-5 8 9.2 water 8 2 I-6 A-3 8 B-1 72 D-3 20 - - water 8 2 I-7 A-1 twenty five B-2 62.5 D-2 12.5 - - water 11 2 I-8 A-1 10.3 B-1 57.3 D-3 7.4 E-4 E-5 E-6 E-7 17.6 4.4 1.5 1.5 water 8 2 I-9 A-1 2.4 B-1 82.4 D-2 11.7 E-1 3.5 water 11 2 I-10 A-1 10.5 B-3 63.2 D-2 10.5 E-1 15.8 water 11 2 I-11 A-1 14.3 B-1 71.4 D-3 14.3 - - water 8 2 I-12 A-3 9.8 B-1 88 D-3 2.2 - - water 8 2 I-13 A-1 10 B-1 62.5 D-3 21.3 E-2 6.2 water 8 2 I-14 A-1 12.7 B-1 79.4 - - E-2 7.9 water 8 2 I-15 A-1 12.5 B-1 50.1 - - E-2 37.4 water 8 2 I-16 A-1 12.7 B-1 79.4 - - E-2 7.9 water 8 2 I-17 A-1 27.4 B-1 64.7 - - E-2 7.9 water 8 2 I-18 A-4 22.2 B-5 77.8 - - - - water 8 2 I-19 A-4 27.4 B-4 64.7 - - E-2 7.9 water 8 2 I-20 A-5 27.4 B-5 64.7 - - E-2 7.9 water 8 2 I-21 A-1 11.8 B-1 54.5 D-1 D-2 6.8 1.8 E-1 E-2 E-3 5 16.9 3.2 water 8 2 I-22 A-1 8 B-1 54 D-3 D-4 6.7 1.3 E-4 E-5 E-6 E-7 E-12 20 4 2 2 2 water 8 2

[0155] Test Category 9 (Preparation of the second treatment diluent for a 2-dose treatment)

[0156] Weigh each component to achieve the content ratio shown in Table 6, stir and mix them to prepare the second treatment agent dilution solution for polyester short fiber water injection (second treatment agent dilution solution (II-1) to (II-6)).

[0157] The types and contents of organophosphate salts (C) and the contents of water in the second treatment agent dilution solutions (II-1) to (II-6) are shown in the "Organophosphate Salts (C)" column and "Soluble" column of Table 6, respectively.

[0158] Table 6 Category Second treatment agent dilution evaluate Second treatment agent solvent preparation stability Organic phosphate salts (C) type share type Relative to a total of 100 parts by weight of the second treatment agent II-1 C-1 100 water 54 2 II-2 C-2 100 water 54 2 II-3 C-3 100 water 54 2 II-4 C-4 100 water 54 2 II-5 C-5 100 water 150 2 II-6 C-6 100 water 43 2

[0159] Test Category 10 (Evaluation of formulation stability of the first treatment agent dilution and the second treatment agent dilution)

[0160] Dispense 10 mL of each of the prepared first and second treatment agent diluents into test tubes, visually observe them, and determine the stability using the following criteria. The results are shown in the "Formulation Stability" column of Tables 5 and 6.

[0161] ・Evaluation criteria for formulation stability 2 (Fair): No separation or precipitation immediately after preparation 1 (Poor): Separation or precipitation occurs immediately after preparation

[0162] Test Category 11 (Preparation of a treatment agent dilution formed by diluting the first treatment agent and the second treatment agent)

[0163] (Example 2-1) The second treatment agent dilution (II-1) shown in Table 6 was added to half of the predetermined amount of water heated to about 50°C under stirring until it was completely dissolved. After dissolution, the first treatment agent dilution (I-1) shown in Table 5 was added under stirring until it was completely dissolved. After dissolution, heating was stopped, and the remaining half of the water at about 25°C was added to it all at once and stirred until homogeneous to obtain a 5% by mass aqueous solution of the treatment agent dilution of Example 2-1.

[0164] (Examples 2-2 to 2-22) The first treatment agent diluent shown in Table 5 and the second treatment agent diluent shown in Table 6 were mixed in the same manner as in Example 2-1 to prepare the treatment agent diluents for each example.

[0165] The types and contents of the first treatment agent diluent and the second treatment agent diluent are shown in the "First Treatment Agent Diluent" column and the "Second Treatment Agent Diluent" column of Table 7, respectively.

[0166] Table 7 category First treatment agent diluent Second treatment agent diluent evaluate type share type share Antistatic electrical Combing web Uniformity Antifoaming properties hydrophilic lotion stability Example 2-1 I-1 51.3 II-1 48.7 3 4 3 3 3 Example 2-2 I-2 51.3 II-2 48.7 3 4 3 3 3 Example 2-3 I-3 44.2 II-1 55.8 3 4 3 3 3 Examples 2-4 I-4 41.2 II-2 58.8 3 4 3 3 3 Examples 2-5 I-5 82.4 II-3 17.6 3 4 3 3 3 Examples 2-6 I-6 41.2 II-3 58.8 3 4 3 3 3 Examples 2-7 I-7 32.5 II-4 67.5 3 4 3 3 3 Examples 2-8 I-8 59.8 II-3 40.2 3 4 3 3 3 Examples 2-9 I-9 80.3 II-3 19.7 2 4 3 3 3 Example 2-10 I-10 93.2 II-4 6.8 2 4 3 3 2 Example 2-11 I-11 27.4 II-2 72.6 3 4 3 2 3 Example 2-12 I-12 36.5 II-3 63.5 3 3 3 3 3 Example 2-13 I-13 73.7 II-2 26.3 3 4 3 3 2 Example 2-14 I-14 68.8 II-2 31.2 3 3 3 2 3 Example 2-15 I-15 31.8 II-2 68.2 3 3 2 2 3 Example 2-16 I-16 57.6 II-5 42.4 2 3 3 2 3 Example 2-17 I-17 57.6 II-5 42.4 2 2 3 2 2 Example 2-18 I-18 87.2 II-6 12.8 2 3 2 2 3 Example 2-19 I-19 57.6 II-5 42.4 2 2 2 2 3 Example 2-20 I-20 57.6 II-5 42.4 2 2 2 2 3 Example 2-21 I-21 16.5 II-1 83.5 3 4 2 3 3 Example 2-22 I-22 22.5 II-2 77.5 3 4 2 3 3

[0167] Test Category 12 (Evaluation of Diluted Treatment Agents for 2 Formulations) Using the diluted treatment agents obtained in Examples 2-1, etc., the antistatic properties, carding web uniformity, antifoaming properties, hydrophilicity, and emulsion stability were evaluated using the same method as the treatment agents in Examples 1-1. The results are shown in the "Antistatic Properties", "Carding Web Uniformity", "Antifoaming Properties", "Hydrophilicity", and "Emulsion Stability" columns of Table 7, respectively.

[0168] As can be seen from the results in the table above, the antistatic properties, carding web uniformity, foam suppression, and hydrophilicity imparted to the fibers by the treatment agent can be improved respectively. In addition, the emulsion stability of the treatment agent dilution can be improved.

Claims

1. A treatment agent for polyester staple fiber water injection, characterized in that: it contains a first fatty acid derivative, a second fatty acid derivative, and an organophosphate salt, wherein the first fatty acid derivative is an adduct formed by at least one of linoleic acid and alpha-linolenic acid with an epoxide, the second fatty acid derivative is an adduct formed by at least one of oleic acid and stearic acid with an epoxide, and the non-volatile components of the above-mentioned polyester staple fiber water injection treatment agent contain a total of 10% to 90% by mass of the first fatty acid derivative and the second fatty acid derivative, and 5% to 80% by mass of the organophosphate salt.

2. The polyester staple fiber water injection treatment agent as claimed in claim 1, wherein the mass proportion of oxyalkylene groups in the molecular structure of the first fatty acid derivative and the second fatty acid derivative is 50% by mass or less.

3. The polyester staple fiber water injection treatment agent as claimed in claim 1, wherein when the mass of the first fatty acid derivative in the polyester staple fiber water injection treatment agent is set as Am and the mass of the second fatty acid derivative is set as Bm, the mass ratio Am / Bm is 0.01 or more and 0.4 or less.

4. The polyester staple fiber water injection treatment agent as claimed in claim 1, wherein the above-mentioned organophosphate salt is a salt of a phosphate ester having an alkyl group having 11 to 13 carbon atoms.

5. The polyester staple fiber water injection treatment agent as claimed in claim 1, wherein the non-volatile components of the polyester staple fiber water injection treatment agent contain a total of 30% to 70% by mass of the first fatty acid derivative and the second fatty acid derivative, and 10% to 60% by mass of the organophosphate salt.

6. The polyester staple fiber water injection treatment agent as claimed in claim 1, wherein it further comprises a diester formed of polyethylene glycol with a molecular weight of 200 to 800 and a monovalent fatty acid with 12 to 20 carbon atoms.

7. The polyester staple fiber water injection treatment agent as claimed in claim 6, wherein the non-volatile components of the polyester staple fiber water injection treatment agent contain a total of 30% to 70% by mass of the first fatty acid derivative and the second fatty acid derivative, 10% to 60% by mass of the organophosphate salt, and 2% to 10% by mass of the diester.

8. A diluent for a polyester staple fiber water injection treatment agent, characterized in that it contains any one of claims 1 to 7 for the polyester staple fiber water injection treatment agent and water.

9. A first treatment agent for polyester staple fiber water injection, used in conjunction with a second treatment agent for polyester staple fiber water injection, characterized in that: the first treatment agent for polyester staple fiber water injection contains a first fatty acid derivative and a second fatty acid derivative, and selectively contains a diester formed by polyethylene glycol with a molecular weight of 200 to 800 and a monovalent fatty acid with 12 to 20 carbon atoms; the first fatty acid derivative is an adduct formed by at least one of linoleic acid and alpha-linolenic acid with an epoxide; the second fatty acid derivative is an adduct formed by at least one of oleic acid and stearic acid with an epoxide; and the second treatment agent for polyester staple fiber water injection contains an organophosphate salt. The above-mentioned first treatment agent for polyester staple fiber water injection and the above-mentioned second treatment agent for polyester staple fiber water injection are used together such that the non-volatile components of the polyester staple fiber water injection treatment agent obtained by mixing the above-mentioned first treatment agent for polyester staple fiber water injection and the above-mentioned second treatment agent for polyester staple fiber water injection contain a total of more than 10% by mass and less than 90% by mass of the above-mentioned first fatty acid derivative and the above-mentioned second fatty acid derivative, and more than 5% by mass and less than 80% by mass of the above-mentioned organophosphate salt.

10. A second treatment agent for polyester staple fiber water injection, used in conjunction with a first treatment agent for polyester staple fiber water injection, characterized in that: the first treatment agent for polyester staple fiber water injection contains a first fatty acid derivative and a second fatty acid derivative, and selectively contains a diester formed by polyethylene glycol with a molecular weight of 200 to 800 and a monovalent fatty acid with 12 to 20 carbon atoms; the first fatty acid derivative is an adduct formed by at least one of linoleic acid and alpha-linolenic acid with an epoxide; the second fatty acid derivative is an adduct formed by at least one of oleic acid and stearic acid with an epoxide; and the second treatment agent for polyester staple fiber water injection contains an organophosphate salt. The above-mentioned second treatment agent for polyester staple fiber water injection and the above-mentioned first treatment agent for polyester staple fiber water injection are used together such that the non-volatile components of the polyester staple fiber water injection treatment agent obtained by mixing the above-mentioned second treatment agent for polyester staple fiber water injection and the above-mentioned first treatment agent for polyester staple fiber water injection contain a total of 10% to 90% by mass of the above-mentioned first fatty acid derivative and the above-mentioned second fatty acid derivative, and 5% to 80% by mass of the above-mentioned organophosphate salt.

11. A polyester staple fiber, characterized in that: it is coated with any one of claims 1 to 7 as a polyester staple fiber water injection treatment agent.